difference in glp 1 2 and 3 Comparing Ozempic, Wegovy Other GLP-1 Drugs Table 3 from Glucagon-Like Peptide-1

F or sensitive skin Introduce only one new product at a time

References Philippou, A., Maridaki, M., Halapas, A., & Koutsilieris, M

Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760

Blum and others began prescribing these lower doses to healthy patients in 2024